Analysts See $-0.06 EPS for Catalyst Pharmaceuticals (CPRX); Ferrellgas Partners LP (FGP)’s Sentiment Is 0.83

August 3, 2017 - By wolcottdaily

Analysts expect Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) to report $-0.06 EPS on August, 8.They anticipate $0.00 EPS change or 0.00% from last quarter’s $-0.06 EPS. After having $-0.06 EPS previously, Catalyst Pharmaceuticals Inc’s analysts see 0.00% EPS growth. The stock decreased 3.62% or $0.1 during the last trading session, reaching $2.66. About shares traded. Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) has risen 267.48% since August 3, 2016 and is uptrending. It has outperformed by 250.78% the S&P500.

Ferrellgas Partners, L.P. is engaged in the retail distribution of propane and related equipment sales, and midstream operations, which include crude oil logistics. The company has market cap of $437.19 million. The Company’s divisions include propane and related equipment sales, midstream operations-crude oil logistics, and corporate and other. It currently has negative earnings. The propane and related equipment sales segment consists of the distribution of propane and related equipment and supplies.

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The company has market cap of $224.92 million. The Firm is focused on developing and commercializing therapies for people with rare debilitating diseases. It currently has negative earnings. The Firm has three drugs in development: Firdapse, CPP-109 and CPP-115.

Among 2 analysts covering Catalyst Pharmaceuticals (NASDAQ:CPRX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Catalyst Pharmaceuticals had 3 analyst reports since April 26, 2016 according to SRatingsIntel. Piper Jaffray upgraded the shares of CPRX in report on Wednesday, October 5 to “Overweight” rating. PiperJaffray upgraded it to “Overweight” rating and $4 target in Wednesday, October 5 report. The stock has “Neutral” rating by Piper Jaffray on Tuesday, April 26.

Investors sentiment increased to 0.94 in Q4 2016. Its up 0.64, from 0.3 in 2016Q3. It improved, as 6 investors sold Catalyst Pharmaceuticals Inc shares while 12 reduced holdings. 9 funds opened positions while 8 raised stakes. 23.81 million shares or 1.65% more from 23.42 million shares in 2016Q3 were reported. Berson & Corrado Inv Advsrs Limited Liability Corporation invested in 190,600 shares or 0.12% of the stock. Morgan Stanley invested in 0% or 12,419 shares. Blackrock Institutional Tru Communications Na holds 469,440 shares or 0% of its portfolio. Provise Grp Ltd Company, Florida-based fund reported 19,000 shares. Broadfin Ltd Liability Corporation reported 8.20 million shares. Venbio Select Advisor Lc has invested 0.24% of its portfolio in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX). Millennium Limited Liability holds 0% of its portfolio in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) for 319,868 shares. Blackrock invested in 0% or 12,442 shares. Vanguard Grp Inc Inc reported 0% in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX). Creative Planning invested in 16,681 shares. Northern Tru Corp invested in 100,396 shares or 0% of the stock. Royal Natl Bank Of Canada stated it has 0% in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX). Blackrock Fund holds 58,345 shares. Kingdon Management Limited Liability has invested 0.04% of its portfolio in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX). Credit Suisse Ag accumulated 0% or 16,005 shares.

Since January 1, 0001, it had 1 insider purchase, and 0 insider sales for $104,758 activity.

Ratings analysis reveals 0 of Ferrellgas Partners’s analysts are positive. Out of 5 Wall Street analysts rating Ferrellgas Partners, 0 give it “Buy”, 4 “Sell” rating, while 1 recommend “Hold”. The lowest target is $6.0 while the high is $14.0. The stock’s average target of $11 is 144.44% above today’s ($4.5) share price. FGP was included in 5 notes of analysts from August 22, 2016. The firm has “Underweight” rating given on Wednesday, September 28 by JP Morgan. Citigroup downgraded the shares of FGP in report on Tuesday, September 13 to “Sell” rating. The firm earned “Underperform” rating on Thursday, September 15 by RBC Capital Markets. As per Monday, December 12, the company rating was maintained by UBS. Piper Jaffray initiated the shares of FGP in report on Monday, August 22 with “Neutral” rating.

Lucus Advisors Llc holds 0.38% of its portfolio in Ferrellgas Partners, L.P. for 24,077 shares. Koch Industries Inc owns 15,771 shares or 0.24% of their US portfolio. Moreover, Novare Capital Management Llc has 0.19% invested in the company for 114,200 shares. The Massachusetts-based Albert D Mason Inc has invested 0.16% in the stock. Fort Point Capital Partners Llc, a California-based fund reported 36,850 shares.

The stock decreased 1.10% or $0.05 on August 2, reaching $4.5. About shares traded. Ferrellgas Partners, L.P. (FGP) has declined 71.41% since August 3, 2016 and is downtrending. It has underperformed by 88.11% the S&P500.